Hiring experienced marketing people lots of things in the pipeline, people got too focused on the legal side.
Two dozen companies looking at EV3.
Plus if the cellphone thing takes off NLST will be $20.
I have made a lot of money buying good old NLST before the annual November small cap pump, and looking for a repeat.
Good luck to all
SMSI strongest quarters are Q3 and Q4.
With $1.30 cash per share and a blockbuster drug, anyone who thinks this will stay below $1 for any period of time is an idiot.
Low float stocks have less liquify and hence get hit the hardest in recent biotech selloff.
Two major catalysts plus Institutions buying back shares sold for tax purposes will provide a violent rebound.
Biotechs have been hammered the last 2 months.
Usually August and September are bad months for small caps as tax loss selling occurs. Usually a big rebound in November when institutions buy back.
Biotechs with small floats like SGNL have been hit the hardest, and will bounce back the fastest.
Options are always priced lower than fair market value as an incentive for management. This is huge. This means WPCS believes fair market value is much higher.
Sebastian Giordano, WPCS International Incorporated's Interim CEO and a director of the company, just received 1,000,000 options from the company. The strike price of the options received was $1.32, and these expire on September 29, 2025. Giordano now owns at least 1,075,130 options on the company.
NLST is going to move big again imo.
Like other small caps, NLST biggest moves have always been in November.
The last two conference calls have mentioned numerous catalysts, including the cellphone deal and partnership discussions.
In last call they also said Q2 would be low point in sales and expected sequential improvement in Q3 and Q4.
Also stated there was strong EV3 interest among many customers.
Also the October 9 Inphi hearing.
-$1.3 per share cash and no debt.
-We are heading into November, the strongest month for small caps. Institutions buy back stocks they sold for tax purposes.
-Results from fosbretabulin in combination with Votrient in THREE WEEKS could be a GAME CHANGER. OXGN SAID EARLY RESULTS WERE INTRIGUING.
-OXGN has a small float so it got hit very hard due to biotech selloff. However, SMALL FLOAT STOCKS ALSO REBOUND THE FASTEST.
-The most successful Hedge fund in the world, Renaissance Technologies, has a large stake in OXGN.
-The top biotech analyst at Seeking Alpha, Daniel Ward, has OXGN as one of the top picks for Q4 2015.